Lutetium PSMA-617 | News Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

3,426 results for “Lutetium PSMA-617”

Lutetium-177-PSMA-617 Shows Promise in Advanced Prostate Cancer Treatment

UpFrontPSMA Trial: Lutetium-PSMA Plus Docetaxel Shows Promise in Metastatic Hormone-Sensitive Prostate Cancer

Real-World Safety Analysis Reveals Key Adverse Event Patterns for Lutetium-177-PSMA-617 in Advanced Prostate Cancer

Real-World Study Highlights Hematological Risks with Lutetium-177-PSMA-617 in Prostate Cancer

Lutetium-177 PSMA-617 Demonstrates Efficacy in Metastatic Castration-Resistant Prostate Cancer

Radionuclide Therapy Shows Promise in Advanced Prostate Cancer Treatment

Lutetium-PSMA Combination Therapies Show Promise in Advanced Prostate Cancer

Preliminary Data on 225Ac-J591 Shows Promise in Treating mCRPC

PSMA PET-CT Criteria Show Promise for Early Prostate Cancer Progression Detection

SPLASH Trial: Lutetium-177 Demonstrates Efficacy in Advanced Prostate Cancer

Page 1 of 54